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The high level of Axl tyrosine kinase expression in various cancer cell lines makes it an
attractive target for the development of anti-cancer drugs. In this study, we carried out
several sets of in silico screening for the ATP-competitive Axl kinase inhibitors based
on different molecular docking protocols. The best drug-like candidates were identified,
after parental structure modifications, by their highest affinity to the target protein. We
found that our newly designed compound R5, a derivative of the R428 patented analog,
is the most promising inhibitor of the Axl kinase according to the three molecular
docking algorithms applied in the study. The molecular docking results are in agreement
with the molecular dynamics simulations using the MM-PBSA/GBSA implicit solvation
models, which confirm the high affinity of R5 toward the protein receptor. Additionally, the
selectivity test against other kinases also reveals a high affinity of R5 toward ABL1 and
Tyro3 kinases, emphasizing its promising potential for the treatment of malignant tumors.
Keywords: Axl tyrosine kinase, anti-cancer drug-like molecules, in silico rational drug design, molecular docking,
molecular dynamics
INTRODUCTION
Receptor tyrosine kinases are transmembrane proteins, which consist of several domains that
are activated upon ligand binding to their extracellular regions, triggering downstream signaling
cascades (Robinson et al., 2000; Myers et al., 2016). They are involved in various regulatory
processes, such as cell survival, growth, differentiation, adhesion, proliferation, and motility
(Robinson et al., 2000; Ségaliny et al., 2015; Myers et al., 2016). Impaired gene functions by
mutations or deletionsmay cause the abnormal expression of protein kinases, which, in turn, entails
tumor formation and progression (Blume-Jensen and Hunter, 2001; Zhang et al., 2008).
One of the frequently identified kinases involved in the formation of various types of tumors is
Axl receptor tyrosine kinase (Craven et al., 1995; Sun et al., 2003). Axl belongs to the TAM family
receptors, which also includes Tyro3 and Mer (O’Bryan et al., 1991; Li et al., 2009). The kinase
structure comprises an extracellular part with two immunoglobulin (Ig)-like domains responsible
for ligand binding, a transmembrane region, and an intracellular domain (O’Bryan et al., 1991;
Lemke and Rothlin, 2008). The growth arrest-specific 6 (Gas6) protein precursor and protein S
are primarily responsible for kinase activation as their ligands (Stitt et al., 1995; Varnum et al.,
1995; Li et al., 2009). Both ligands share a similar domain composition. In particular, they include
two sex-hormone-binding globulin domains at the C-terminus, both with the laminin G1 and
G2 proteins necessary for the subsequent binding to the Ig-like domain of the receptor, causing
their dimerization and activation (Lemke and Rothlin, 2008). Close to the N-terminal, there
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are epidermal-growth-factor-like repeats and, the so-called, Gla-
domain that consists of gamma-carboxyglutamic acid, which is
necessary for binding to phosphatidylserine of the apoptotic cell
membrane in a vitamin-K-dependent reaction (Hasanbasic et al.,
2005; Sasaki et al., 2006; Li et al., 2009).
Axl overexpression has been detected in a majority of human
cancers, including acute myeloid leukemia (Rochlitz et al., 1999;
Hong et al., 2008), breast cancer (Berclaz et al., 2001; Zhang
et al., 2008; Gjerdrum et al., 2010), gastric (Wu et al., 2002) and
lung cancer (Shieh et al., 2005), melanoma (Quong et al., 1994),
osteosarcoma (Han et al., 2013), renal cell carcinoma (Gustafsson
et al., 2009), etc. Therefore, targeting the Axl to inhibit its
function might be a promising strategy for the treatment of
various malignant tumors. Different strategies of targeting the
Axl have already been considered. For instance, Rankin and
Giaccia (2016), in their review, highlight the three classes of Axl
inhibitors directed on cancer therapy. The first class includes
small-molecule tyrosine kinase inhibitors that block Axl kinase
activity (Rankin and Giaccia, 2016). The second class consists of
anti-Axl antibodies (Rankin and Giaccia, 2016) that block Axl
activation, which is triggered by the Axl–Gas6 interaction, and
the third class comprises soluble Axl decoy receptors (Rankin and
Giaccia, 2016) that serve as a trap for Gas6, hence, preventing the
Axl–Gas6 binding.
Different experimental and computational techniques have
been developed and applied in the last decades for rational drug
design and discovery (Baldi, 2010; Ou-Yang et al., 2012; March-
Vila et al., 2017). For instance, computational and experimental
approaches focused on in silico design and organic synthesis
of the Axl kinase inhibitors have already been performed by
Mollard et al. (2011). In their research, the authors constructed
a homology model for the active site of the Axl kinase and
performed docking experiments for the designed compounds.
Recently, the three-dimensional (3D) structure of the Axl
kinase in a complex with its inhibitor (macrocyclic compound
1) has been successfully solved by Gajiwala et al. (2017)
using differential scanning fluorimetry and hydrogen–deuterium
exchange mass spectrometry. This 3D structure, as a tetrameric
configuration, consists of two active (B and D chains) and two
inactive (A and C) motifs in a complex with a small ATP-
competitive inhibitor. The active and the inactive states are
characterized by the DFG (Asp-Phe-Gly) loop-in and loop-
out conformations.
According to the mode of binding, all tyrosine kinase
inhibitors have been divided into different types. In their review,
Zhang et al. (2009) distinguishes four basic types of inhibitors.
According to this classification, the type I and the type II
inhibitors bind to the DFG-in and DFG-out motifs, respectively.
Additionally, the type III inhibitors interact with the protein
outside the highly conserved ATP-binding pocket, representing
allosteric binding and, therefore, named as allosteric inhibitors
(Wu et al., 2015). Finally, the type IV inhibitors bind the active
site irreversibly, forming covalent bonds within the binding
pocket. A slightly expanded classification of the protein kinase
inhibitors is suggested by Roskoski (2016).
In the current study, we introduce systematic computational
analysis for the DFG-in conformation of the Axl kinase to inhibit
its activity using different sets of molecular docking algorithms
andmolecular dynamics simulation techniques to handle cancer-
related diseases.
COMPUTATIONAL METHODS
3D Structure Derivation
The 3D coordinates for the Axl kinase in a complex with the
macrocyclic compound 1 have been retrieved from protein data
bank (PDB) under the reference code 5U6B. Other kinases
such as ABL1, ALK5, FYN, JAK, MER, MET, and Tyro3 have
been derived under the 4WA9, 3GXL, 2DQ7, 5WO4, 5U6C,
2WD1, and 3QUP PDB codes, respectively. Coordinates for
the Axl kinase type I inhibitors have been obtained from the
PubChem under the following CIDs: 46215462 (R428), 11282283
(Amuvatinib), 5328940 (Bosutinib), 11626560 (Crizotinib),
49803313 (Gilteritinib), 49870909 (S49076), 46870258 (SGI-
7079), 5329102 (Sunitinib), 56839178 (TP-0903), and 73425588
(UNC2025). The PubChem CIDs for the 136 R428 patented
analogs as well as the 26 analogs of crizotinib can be found in
the Supplementary Material.
Structure Preparation
All compounds were energy-minimized prior to docking, with
the help of the Molecular Operating Environment (MOE)
software [Molecular Operating, Environment (MOE), 2016],
using MMFF94 (Merck Molecular Force Field) with the gradient
convergence set to 0.01 kcal/mol and saved in.pdb and.mol2
formats. Further structural modifications of the best-scoring
compounds were also performed with the help of the MOE
software [Molecular Operating, Environment (MOE), 2016].
Protein structure refinement as well as ligand libraries have been
prepared with the tools of the same software.
Docking
Molecular docking simulations have been performed with the
help of well-validated (Chan and Labute, 2010; Forli et al., 2016)
software such as GOLD (Jones et al., 1997), MOE [Molecular
Operating, Environment (MOE), 2016], and AutoDock
(Morris et al., 2009).
GOLD
Molecular docking using the GOLD software was performed
using version 5.5 (Jones et al., 1997). The binding site
residues were defined by specifying the crystal structure ligand
coordinates bound to the protein and using the default cutoff
radius of 6 Å, with the “detect cavity” option enabled. The
GOLD docking experiments were performed using the ChemPLP
scoring function. For each compound, 50 complexes were
generated. The highest-scoring compounds were selected as the
most appropriate ones.
MOE
Docking has been performed by selecting the default “Rigid
Receptor” protocol. As a binding site, the coordinates of
co-crystalized ligand atoms have been selected. The ligand
placement was performed using the Triangle Matcher protocol.
The top 30 poses were ranked by London dG scoring function,
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FIGURE 1 | The superposition of the crystal structure of macrocyclic compound 1 (shown in forest green) with its docked pose performed by the GOLD (A, orange),
MOE (B, deep pink), and AutoDock (C, yellow) software. The protein is represented as a secondary structure and highlighted in cyan. Some of the pocket residues are
shown in licorice and colored in purple.
and the resulting five poses were identified using the generalized-
Born-volume-integral/weighted-surface-area function. The
conformations with the more negative final score were
considered as favorable.
AutoDock
Molecular docking using AutoDock software (Morris et al.,
2009) has been performed using version 4.2.6 (available at:
http://autodock.scripps.edu). The AutoDock tools were used to
generate the input parameter files for docking. For the current
study, the receptor was considered as a rigid molecule, while
the ligands contained rotatable bonds. Pure protein was applied
for the docking, while all non-protein moieties were removed.
Additional hydrogen atoms were added to the receptor, and
the new PDB coordinates were saved. The ligand PDB file was
modified by the addition of groups representing the Gasteiger
charges. The volume of the grid box was set as 50 × 50 × 50 Å,
with 0.375-Å spacing. The center of the grid box was placed so
that it coincided with the center of the co-crystalized structure of
the compound (macrocyclic compound 1). A genetic algorithm
was selected to set the search parameters. The number of docking
runs was fixed to 50. The conformations with the lowest binding
energies have been selected for further analysis.
The figures were prepared using the UCSF Chimera (Pettersen
et al., 2004; available at: http://www.rbvi.ucsf.edu/chimera)
and the MOE [Molecular Operating, Environment (MOE),
2016] software.
Molecular Dynamics
All molecular dynamics (MD) simulations were performed using
the AMBER 16 package (Case et al., 2005) with the FF99SB
and GAFF force fields for the Axl protein and its ligands.
The systems were solvated with the TIP3P water models and
neutralized by adding the Na+ ions using the tLEap input script
available from the AmberTools package. Long-range electrostatic
interactions were modeled via the particle–mesh Ewald method
(Essmann et al., 1995). The SHAKE algorithm (Miyamoto and
Kollman, 1992) was applied to constrain the length of covalent
bonds, including the hydrogen atoms. Langevin thermostat was
implemented to equilibrate the temperature of the system at
300K. A 2.0-fs time step was used in all of the MD setups. For the
minimization and equilibration (NVT ensemble) phases, 10,000
steps and 1-ns time period were used, respectively. Finally, 50-ns
classical MD simulations, with no constrains as NPT ensemble,
were performed for each of the protein–ligand complexes using
the molecular mechanics combined with the Poisson–Boltzmann
(MM-PBSA) or generalized Born (MM-GBSA) augmented with
the hydrophobic solvent-accessible surface area term (Kollman
et al., 2000; Shityakov et al., 2017). The MM-PBSA/GBSA
solvation models were applied as a post-processing end-state
method to calculate the free energies of molecules in the solution
by means of the optimized python script (MM-PBSA.py).
RESULTS
Validation of the Binding Poses
To validate the poses of the ligands, we performed docking
of the co-crystalized ligand–macrocyclic compound 1 (Gajiwala
et al., 2017) to the ATP-binding pocket of the Axl kinase using
the GOLD, MOE and AutoDock simulation software. Figure 1
demonstrates the superposition of the crystal structure of the
ligand (always shown in forest green) and the docked pose of
the same ligand performed by the GOLD (orange, Figure 1A),
MOE (deep pink, Figure 1B), and AutoDock (yellow, Figure 1C)
software. The calculated RMSD values for this ligand are below
the commonly accepted threshold of 2.0 Å, indicating the validity
of the above-mentioned docking engines for the prediction of the
ligand binding pose. The most accurate results were reproduced
by the GOLD and AutoDock software, with the calculated RMSD
values of 0.2 and 0.5 Å, respectively (Figures 1A,C). A less
accurate result was shown by the MOE software, where the
RMSD between the crystal structure and the docked pose was
1 Å (Figure 1B).
Docking of ATP-Competitive Type I
Inhibitors
The first round of in silico testing was performed on the
commercially available ATP-competitive Axl kinase type I
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TABLE 1 | Scores for the ATP and the ATP-competitive type I kinase inhibitors
obtained from the docking performed by the GOLD, MOE, and AutoDock
software.
Compound Score
(GOLD)
Score, kcal/mol
(MOE)
1G, kcal/mol
(AutoDock)
ATP 55.59 −7.34 −4.43
Bosutinib 60.44 −7.60 −8.94
Gilteritinib 61.44 −8.29 −9.15
SGI-7079 61.96 −7.57 −8.80
TP-0903 66.83 −7.58 −8.74
Crizotinib 79.32 −7.78 −9.11
Amuvatinib 63.15 −7.16 −8.37
UNC2025 72.72 −7.26 −9.64
S49076 66.97 −7.04 8.08
Sunitinib 58.35 −6.8 −7.25
Compound13 69.5 −6.97 −9.62
Macrocyclic compound 1 78.98 −7.64 −9.14
R428 75.89 −7.59 −10.04
The top three scores are highlighted in italics.
inhibitors using the molecular docking protocols. From Table 1,
it is clear that the scoring functions from the molecular docking
results indicate a better affinity for the analyzed drugs in
comparison to the ATP, which was used here as a reference.
The top scores belong to macrocyclic compound 1, crizotinib,
and R428 according to the three independent molecular docking
protocols. The last two substances were chosen as the core
components for the structure similarity search and in silico
chemical modifications based on their ability to block specific
kinases that are highly expressed in malignant cells (Solomon
et al., 2014; Chen et al., 2018).
Molecular Docking of R428-Based Analogs
Next, the drug R428 was subjected to the structure similarity
search using the PubChem search algorithm (Kim et al., 2016).
The results came up with 136 patented analogs, which are
suitable for the GOLD/MOE molecular docking to determine
the top 10 hit molecules (Table 2). Within this group the
best four compounds (Table 3) with PubChem CID numbers
67104315 (R428_1), 67104254 (R428_2), 67103757 (R428_3),
and 67103760 (R428_4) were selected for further analysis. The
2D protein–ligand interaction diagrams (see Figures 2A–D) were
drawn for these molecules to demonstrate the binding modes of
the ligands within the Axl receptor binding pocket. So, the amino
groups of R428_2-4 establish the interaction with D690. Besides
an interaction with D690, an additional interaction was observed
between the aromatic ring of compound R428_1 and N676.
Moreover, the R428_2-4 ligands adopt similar conformational
rearrangements within the Axl binding pocket as observed from
Figures 3A,B. The calculated RMSD values for the R428_4
and R428_2 compounds, with respect to the reference R428_3
compound, are 0.8 and 2.3 Å, respectively. On the other hand,
R428_1 is more shifted with respect to the plane of the other three
compounds (see Figure 3A) due to the bigger number of rings in
TABLE 2 | The PubChem CID and scores for the top 10 out of 136 R428 analogs
according to the docking results performed by the GOLD and MOE software.
No. GOLD MOE
PubChem CID Score PubChem CID Score, kcal/mol
1 67104315 88.1 25127087 −8.7
2 46843782 83.3 67103760 −8.6
3 90974101 83.5 46843985 −8.6
4 67104254 83.6 67103757 −8.5
5 67103757 84.1 67104254 −8.5
6 46843846 82.3 66694833 −8.4
7 67537596 81.1 25126441 −8.4
8 67103760 82.6 67103984 −8.4
9 46843917 81.2 67104315 −8.4
10 46843983 80.7 67104240 −8.2
The CIDs of the compounds corresponding to the best scores are shown in italics.
themolecule, thus reducing its flexibility. The RMSD value in this
case is 5.7 Å.
Molecular Docking of Crizotinib-Based
Analogs
A similar structural search was applied to crizotinib to ensure the
identification of the crizotinib-based analogs. The search results
provided 26 analogs for further GOLD/MOE screening. Finally,
the top five compounds were determined (Table 4), but none of
them was subjected to in silico chemical modifications due to
their lesser binding affinity than crizotinib itself. Therefore, the
parental structure was modified to improve its binding properties
toward the Axl kinase.
In silico Design of the Refined Compounds
R428_1 Modifications
To enhance the binding affinity of the identified top compounds
(Table 3), we devised the structural modification scheme for
R428_1. Its invariant part was estimated from the best protein–
ligand binding mode, forming the “scaffold” to adjust the ligand
conformation inside the binding pocket (Figure 4). Therefore,
we decided to design the new compounds by implementing
this part as a template and adding the molecular extensions (X,
Y, and Z) into the “scaffold” at the locations indicated by the
arrows. So, the first six compounds (R1–R6) were designed: the
compound R1 has been derived by adding piperidine bound to a
tri-cyclic moiety (see Figure 4), the compound R2 was formed
by adding a triazole-like ring also connected with a tri-cyclic
moiety, the compound R3 was derived by adding a histidine-
bound triazole ring, the compound R4 was formed by adding two
repeats of triazole-like rings, the compound R5 was achieved by
extending the template structure with a tyrosine-bound triazole-
like ring, and the compound R6 has been derived by adding to
the template an NH2 group. The next four compounds (R7–R10)
have been derived from the above-mentioned designed R6 and
R3 compounds with a slight alteration of the template structure.
Thus, the compound R7 was obtained by replacing a hydrogen
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TABLE 3 | Four best R428 analogs according to the GOLD and MOE molecular docking scores.
Compound PubChem CID 2D structure Score (GOLD) Score, kcal/mol (MOE)
R428_1 67104315 88.1 −8.6
R428_2 67104254 83.6 −8.5
R428_3 67103757 84.1 −8.5
R428_4 67103760 82.6 −8.6
FIGURE 2 | The 2D interaction diagrams of the R428_1 (A), R428_2 (B), R428_3 (C), and R428_4 (D) compounds with the Axl kinase pocket.
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FIGURE 3 | (A) The superposition of the top four out of best 10 R428 analogs according to the MOE and GOLD docking results. The compound R428_1 is shown in
red, the compound R428_2 is shown in orange, the compound R428_3 is shown in yellow, and the compound R428_4 is shown in green. The backbone of the
kinase is represented as a cartoon and shown in cyan; the key residues inside the pocket are highlighted in purple. The hydrogen bond between the R428_2, R428_3,
and R428_4 compounds and D690 is marked as a blue line. (B) Superposition of the R428_2, R428_3, and R428_4 compounds for a better representation of their
conformational coincidence.
TABLE 4 | The PubChem CID and the scores for the top five out of 26 crizotinib
derivatives according to the docking results performed by the GOLD and MOE
software.
No. GOLD MOE
PubChem CID Score PubChem CID Score, kcal/mol
1 56671943 80.4 11656580 −7.9
2 54579455 80.2 54579455 −7.7
3 11647760 77.5 56671943 −7.6
4 72199381 77.1 11662380 −7.4
5. 11612136 76.0 11576617 −7.4
atomwith a hydroxyl group in the compound R6. The compound
R8, in turn, was obtained by replacing an amino group with a
nitroso group in the compound R6. The compound R9 represents
a pure template (see the upper-left part of Figure 4). Finally, the
compound R10 has been derived by replacing an aromatic amino
group with a nitroso group in the compound R3.
The newly designed compounds were tested by docking to
the ATP-binding site of the Axl kinase. Improved binding results
according to the GOLD, MOE, and AutoDock software were
obtained for the designed R3, R5, and R10 compounds (see
Table 5). In particular, they score higher than the top R428
derivatives (see Table 2). The superposition of R3, R5, and R10
inside the ATP-binding pocket of the Axl kinase shows a similar
level of spatial occupancy (see Figure 5). However, shifts as
well as differences in orientations of the tri-cyclic rings are
observable. The compound R3 (Figure 5, deep pink) is oriented
so that it obtains a “horseshoe-like” conformation inside the
binding pocket and points its tri-cyclic moiety toward N677,
the compound R5 (Figure 5, orange) obtains a slightly extended
conformation and exposes its tri-cyclic ring to D690, while
the compound R10 (Figure 5, olive green) is oriented opposite
from the R3 and the R5 direction, pointing an amino group
toward D690.
All of the newly designed compounds, except R4 and R8,
form hydrogen bonds (H-bonds) with D690 (see Table 6). The
compounds R1–R3 and R10 form an H-bond with N677, while
the compounds R2–R4, R6, and R8 form an H-bond with
M623. Additionally, the compound R2 forms an H-bond with
G626, the compound R3 forms an H-bond with K624, the
compound R4 forms an H-bond with A562, the compound R5
forms an H-bond with H625, and the compound R8 forms
an H-bond with P621. Van der Waals interactions have been
observed as well between the pocket residues and the designed
compounds. So, the compounds R1–R5, R7, R9, and R10, besides
the above-mentioned residues, additionally make interactions
with L542. The compounds R6 and R8, in turn, make interactions
with A565.
R428_2, R428_3, and R428_4 Modifications
Next, we tried to obtain new compounds with improved
binding based on the R428_2, R428_3, and R428_4 structural
characteristics. Since these compounds share an almost identical
structure and acquire a quite similar conformation inside the
pocket (see Figures 2, 3B), we selected a common structural
feature that is shared among these compounds (see the upper-
left part in Figure 6) and used it as a template for further
chemical modifications. Figure 6 describes a stepwise process of
the design of the new (R1′-R11′) compounds. So, the compound
R1′ has been derived by the addition of but-2-enylazanium to the
part indicated with an arrow (upper-left part of Figure 6). The
compound R2′ has been derived by adding an amino group, the
compound R3′ has been formed by adding an aromatic ring, the
compound R4′ has been derived by replacing a single aromatic
ring (indicated with a dashed green circle) in a template by
double aromatic rings, and the compound R5′ has been formed
by the replacement of two aromatic carbons with double-bonded
nitrogen atoms in the structure of R4′. The compound R6′ has
been obtained by adding an extended aliphatic chain to the
template, and the compound R7′ has been derived by adding
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FIGURE 4 | The design strategy of the new compounds starting from the R428_1 compound (see Table 3). The upper-left part is an invariant part of the compound
used as a template. The upper/lower right and lower left parts are extensions/modifications of the template.
a chain with an arginine-like termination. The compound R8′
has been derived similarly to compound R7′, however with a
carbonyl termination. The compound R9′ has been formed by
adding to the aliphatic extension an aromatic ring containing a
hydroxyl group, the compound R10′ has been obtained similarly
to the compound R9′, however with the absence of a hydroxyl
group, and, finally, the compound R11′ contains an extension
with a tryptophan-like termination.
Table S1 reports the docking scores for the above-mentioned
modifications. The compounds did not show significant
improvements of the binding scores compared to the original
compounds—R428_2, R428_3, and R428_4 (please refer to
Table 2 and Table S1). However, improvements were noticed for
the designed compounds R9′ and R10′. For both compounds, the
scores were ∼85 (by GOLD) and −8 (by MOE) (see Table S1).
We, therefore, did not perform a further analysis on these
compounds as they did not demonstrate binding affinities that
are stronger than the ones of R428_1 modifications (please refer
to Table 5).
Crizotinib Modifications
Figure 7 describes the crizotinib modifications. In the upper-left
part of the figure, the 2D structure of crizotinib is demonstrated.
The strategy of the design is based on the following scheme:
each consecutive compound is derived from a previous one via
the modification of a single group present in the structure. The
parts that underwent modifications are indicated with dashed
circles. Thus, the compound C1 is derived by the replacement
of a fluorine atom, indicated with a violet dashed circle, with a
hydroxyl group; the compound C2 is derived from compound
C1 by the replacement of an amino group, indicated with a red
dashed circle, with a hydroxyl group; the compound C3 is derived
from compound C2, where the pyrazole ring, indicated with a
dashed green circle, is replaced by a pyran ring; the compound
C4 is derived from the compound C3 by the replacement of
a chlorine atom, indicated by a purple ring, with a hydroxyl
group; the compound C5 is derived from the compound C4
by the replacement of an aminocyclohexane group, indicated
with a dashed magenta circle, with a cyclopropane group;
the compound C6 is derived from the compound C5 by the
replacement of a cyclopropane group with cyclooctane; the
compound C7 is derived from the compound C6 by the
replacement of cyclooctane with 3-hydroxy-5-amino-pentane,
the compound C8 is derived from the compound C7 by the
replacement of two cyclohexanes, indicated with a dashed cyan
circle, with a triple aromatic network; the compound C9 is
derived from the compound C8 by adding to a triple aromatic
network one more hydroxyl group, and, finally, the compound
C10 is derived from the compound C9 by double modifications:
first, by the replacement of a hydroxyl group in a triple aromatic
network with fluorine atoms and, second, by the replacement
of 3-hydroxy-5-amino-pentane with 1-cyclopenta-1,3-dien-1-
ylbutan-2-ol.
Table S2 shows the docking results for the crizotinib
modifications—compounds C1–C10. The possible alterations
in the structure of crizotinib did not result in a significant
binding improvement. Therefore, we did not consider these new
derivatives for further analysis.
Validation of Docking Results
To estimate the strength of our best-designed compound R5, we
have compared the calculated inhibition constants (K i) as well as
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TABLE 5 | Docking scores according to the GOLD, MOE, and AutoDock software for the newly designed compounds—modifications of R428_1.
Compound no. 2D structure Score (GOLD) Score, kcal/mol (MOE) 1G, kcal/mol (AutoDock)
R1 74.0 −9.4 −6.4
R2 89.6 −9.2 −11.0
R3 91.3 −10.5 −10.7
R4 80.5 −8.0 −10.5
R5 98.6 −10.0 −11.7
R6 66.7 −7.2 −10.7
R7 69.2 −7.3 −10.7
R8 70.8 −8.0 −10.6
R9 69.7 −7.3 −10.4
R10 93.7 −10.0 −11.1
The top four scores are highlighted in italics.
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FIGURE 5 | The superposition of the three top-scoring compounds designed.
The compound R3 is shown in deep pink, the compound R5 is shown in
orange, and the compound R10 is shown in olive green. The backbone of the
kinase is represented as a secondary structure and highlighted in cyan; some
of the key residues in the binding pocket—D690, N677, and L542—are shown
as licorice and indicated in purple.
TABLE 6 | The list of cavity residues involved in the H-bond formations as well as
in the short-range van der Waals interactions with the designed compounds
R1–R10 according to the GOLD software.
Compound
no.
H-bond van der Waals interactions
R1 D690, N677 H629, D690, G626, R676, M629,
F622, V550, L542
R2 D690, N677, M623, G626 D690, H629, A565, L542, M623
R3 D690, N677, M623, K624 D690, R676, L542, M623, K624,
H625
R4 A562, M623 D690, R676, M623, K624, L542,
A565
R5 D690, H625 D690, M623, L542, G626
R6 D690, M623 A565, M623, R676
R7 D690 L542, K567, E546, G545
R8 D627, M623, P621 M598, V550, A565, P621, M623
R9 D690 M598, L542, D690, K567, E546,
G545
R10 K624, D627, N677, D690 D639, K624, L542, N677
the ligand efficiencies (LE) for ATP, R428, R428_1, and R5. The
data are reported inTable 7. As the results show, the highest value
of inhibition constant belong to ATP (566µM). R428 shows the
value of K i to be 12 times lower than that of ATP, indicating a
highly competitive binding of the R428 over ATP. The compound
R428_1 exhibits an even lowerK i than the R428 itself, and, finally,
the newly designed compound R5 shows the lowest value of K i
(2.3 nM), which is 19 times lower than that of the R428. The
calculated LE for R428, R428_1, and R5 compounds are showing
almost the same values; the LE for the ATP is slightly lower than
for the above-mentioned compounds. Taken together, these data
indicate the high efficiency of the newly designed compound R5.
To validate further the molecular docking results, the free
energies of binding (1Gbind) based on the implicit solvation
models were calculated for R428, its best derivative—compound
R428_1, the best-designed compound R5 and ATP as a reference
molecule, establishing the best ligand affinity to the Axl kinase.
The MM-PBSA/GBSA calculations (Tables 8, 9), using the 50 ns
MD trajectories, confirm the previous data: the compound R5 has
a much higher affinity to the Axl protein in MM-PBSA (Table 8).
However, the MM-GBSA test provides the same affinity to Axl
for this structure as the R248 derivative form (Table 9). This
outcome might be explained in such a way that the MM-PBSA
model is the more “optimized,” providing the data, which are
more in agreement with molecular docking experiments. This
“hysteresis” phenomenon has been previously observed in the
MD experiments for cyclodextrin-based complexes to assess their
drug delivery potential at the blood–brain barrier (Shityakov
et al., 2016a,b).
On the other hand, the entropy–enthalpy compensation
analysis revealed significant differences only in the Axl–ATP
thermodynamics, being either an exothermic (MM-GBSA)
or an endothermic (MM-PBSA) binding reaction (Table 10).
Nevertheless, the experimental binding enthalpy from the
previous study was found to be negative for nucleotide binding
to creatine kinase (Forstner et al., 1999), indicating the possibility
of an exothermic binding event for Axl–ATP. Similarly, the
R428-based compounds exhibited more negative 1H values,
suggesting the enthalpy-driven binding process.
Selectivity Test
To establish how selective the best-designed compound R5
toward Axl kinase is, we further performed a selectivity test
against a set of other kinases such as ALK5 (Gellibert et al.,
2009), ABL1 (Pemovska et al., 2015), FYN (Kinoshita et al.,
2006), JAK1 (Siu et al., 2017), MET (Porter et al., 2009), Tyro3
(Powell et al., 2012), and Mer (Gajiwala et al., 2017). Table 11
reports the docking results for the compound R5 to the kinases
according to the three different software—GOLD, MOE, and
AutoDock. The best binding scores are highlighted in italics (see
Table 11). According to the docking results, the compound R5
has shown quite good binding scores for the studied kinases,
which means that the compound R5 can be further applied to
target the above-mentioned kinases. Among the studied kinases,
improved binding has been observed toward ABL1 and Tyro3.
Interestingly, the docking of the compound R5 to the Tyro3
binding site resulted in the highest score among all kinases
considered, including the primary target—the Axl kinase. This
result indicates a high selectivity of the compound R5 not only
toward Axl (please refer to Table 5) but also to another TAM
family member—the Tyro3 kinase.
DISCUSSION
The expression of Axl kinase was found in various types of tumor
cells (see Table 12), making this protein a promising target for
novel anti-cancer pharmaceuticals. Despite the fact that there
are some Axl inhibitors in the market (Myers et al., 2016), the
selectivity of drugs might be a serious obstacle to overcome in
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FIGURE 6 | The strategy of the design of the new compounds based on the R428_2, R428_3, and R428_4 template extension. The upper-left part is a template. The
upper- and lower-right parts are extensions/modifications of the template.
FIGURE 7 | A schematic representation of the crizotinib modifications. The upper-left part is a template that undergoes modifications (indicated by dashed circles).
The upper-right and lower-right/left parts are extensions/modifications of the template.
order to improve their efficacy. Therefore, the novel drug-like
molecules with an improved selectivity to a certain type of kinase
might potentiate the therapeutic effect against malignant tumors.
To follow this path, molecular docking and molecular
dynamics simulation approaches were devised and implemented
to compare the binding affinities of known Axl kinase
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TABLE 7 | The inhibition constant and the ligand efficiency as calculated by the
AutoDock software for the ATP, R428, best existing R428 analog—compound
R428_1, and best designed compound R5—R428_1 derivative.
Compound Inhibition constant (Ki) Ligand efficiency (LE)
ATP 566µM −0.14
R428 44 nM −0.26
R428_1 31.2 nM −0.23
R5 2.29 nM −0.21
TABLE 8 | Energetic analysis of the receptor–ligand complexes using the
MM-PBSA implicit solvation model.
Term (kcal/mol) Axl–ATP Axl–R428 Axl–R428_der Axl–comp_R5
1EvdW −42.49 −80.51 −91.99 −98.84
1EEL 127.21 −2.59 −3.28 −11.55
1EPB −87.06 26.65 29.59 32.79
1ENPOLAR −26.03 −36.75 −40.68 −45.12
1EDISPER 52.22 77.39 89.66 97.81
1Ggas 84.72 −83.09 −95.28 −110.39
1Gsolv −60.87 67.29 78.57 85.48
1Gbind 23.85 −15.8 −16.7 −24.91
TABLE 9 | Energetic analysis of the receptor–ligand complexes using the
MM-GBSA implicit solvation model.
Term (kcal/mol) Axl–ATP Axl–R428 Axl–R428_1 Axl–comp_R5
1EvdW −42.49 −80.51 −91.99 −98.84
1EEL 127.21 −2.59 −3.28 −11.55
1EGB −83.39 18.86 18.62 34.89
1ESURF −5.66 −7.14 −7.74 −8.43
1Ggas 84.72 −83.09 −95.28 −110.39
1Gsolv −89.05 11.72 10.88 26.47
1Gbind −4.33 −71.38 −84.39 −83.93
TABLE 10 | Entropy–enthalpy compensation analysis of the receptor–ligand
complexes from 50 ns MD simulations.
Term (kcal/mol) Axl–ATP Axl–R428 Axl–R428_1 Axl–comp_R5
T1S (T = 298.15K) −18.22 −18.64 −28.15 −41.98
1Ha −22.55 −90.02 −112.54 −125.91
1Hb 5.63 −34.44 −44.85 −66.89
a
∆GMM−GBSA = ∆H–T∆S.
b
∆GMM−PBSA = ∆H–T∆S.
inhibitors (Myers et al., 2016) and to design some novel
drug candidates. We purposely did not implement here a
completely new simulation strategy, but rather followed a well-
validated modeling path, which has been successfully applied by
experimental scientists in the design of new active compounds
(Li et al., 2011; Mollard et al., 2011; Dakshanamurthy et al., 2012;
Heifetz et al., 2012). It is worth to note that docking, despite its
limitations, is a well-established and an experimentally approved
technique for the prediction of potential active substances. For
TABLE 11 | The docking scores for the compound R5 against ALK5, ABL1, FYN,
JAK1, MET, Tyro3, and Mer according to the GOLD, MOE, and AutoDock
software.
Kinase Score (GOLD) Score, kcal/mol
(MOE)
1G, kcal/mol
(AutoDock)
ALK5 93 −8.5 −12.3
ABL1 109 −9.0 −11.3
FYN 94 −8.5 −9.0
JAK1 96 −8.8 −7.7
MET 80 −8.35 −9.7
Tyro3 110 −9.0 −14.1
Mer 95 −9.0 −7.3
The best binding scores are indicated in italics.
TABLE 12 | Expression of the Axl kinase in the different types of cancer cells.
Cancer type References
Acute myeloid leukemia Rochlitz et al., 1999; Hong et al., 2008
Astrocytoma Vajkoczy et al., 2006; Keating et al., 2010
Breast cancer Berclaz et al., 2001; Meric et al., 2002;
Gjerdrum et al., 2010
Colorectal Craven et al., 1995; Dunne et al., 2014
Esophageal adenocarcinoma Hector et al., 2010; Hsieh et al., 2016
Glioblastoma multiforme Hutterer et al., 2008
Gastrointestinal stromal tumor Mahadevan et al., 2007
Gastric cancer Wu et al., 2002
Head and neck squamous cell
carcinoma
Brand et al., 2015
Hepatocellular carcinoma Liu et al., 2016
Kaposi sarcoma Liu et al., 2010
Lung adenocarcinoma Shieh et al., 2005; Ishikawa et al., 2013
Melanoma Müller et al., 2014
Oral squamous carcinoma Lee et al., 2012
Osteosarcoma Nakano et al., 2003
Ovarian adenocarcinoma Chen et al., 2013; Rea et al., 2015
Pancreatic ductal adenocarcinoma Koorstra et al., 2009
Renal cell carcinoma Gustafsson et al., 2009
Pleural mesothelioma Pinato et al., 2013
Urothelial carcinoma Hattori et al., 2016
Prostate cancer Sainaghi et al., 2005
Thyroid cancer Ito et al., 1999
Uterine endometrial cancer Sun et al., 2003
instance, Li et al. (2011) used a docking method to test 4,621
approved drugs from DrugBank against the crystal structure of
MAPK14 to identify a potential anti-inflammatory drug for the
treatment of chronic myeloid leukemia. The study revealed a
potent inhibitor—the drug nilotinib, with an in vitro IC50 of
40 nM (Li et al., 2011). Dakshanamurthy et al. (2012) showed
another successful application of computational modeling in
drug discovery. In theirmethodology, the drug–target interaction
among 3,671 FDA-approved drugs and 2,335 human protein
crystal structures was predicted with 91% accuracy. In addition,
Dakshanamurthy et al. discovered that the anti-parasitic drug
Frontiers in Chemistry | www.frontiersin.org 11 February 2020 | Volume 7 | Article 920
Sarukhanyan et al. Axl Kinase Inhibitors Against Cancer
mebendazole also revealed anti-cancer properties, with a strong
inhibition activity against vascular endothelial growth factor
receptor 2. The results were confirmed experimentally to the
extent that effective treatment of different medulloblastoma
models could be shown by applying mebendazole, including a
clear impact on tumor angiogenesis (Bai et al., 2015).
Purely computational studies targeted on the understanding
of agonists/antagonist interaction with a certain type of receptor
for the design of new medications were performed recently.
In particular, Zhu et al. (2019) applied a combination of
in silico tools such as the 3D-QSAR, molecular docking,
molecular dynamics, and free energy calculation to clarify a
selectivity mechanism of glycogen synthase kinase 3β toward
ATP-competitive inhibitors. They identified some key selective
residues that might play an important role in the design
of the novel ATP-competitive inhibitors (Zhu et al., 2019).
Martínez-Campos et al. (2019) in their work employedmolecular
docking: firstly the QSAR method to analyze all known gamma
aminobutyric acid (GABAB) receptor agonists and later a
structure-based drug design strategy for the design of the novel
compounds. They came up with six potent baclofen analogs
targeted on the activation of the GABAB receptor (Martínez-
Campos et al., 2019). Liu et al. (2019) used virtual screening,
molecular docking, and molecular dynamics tools to identify
the potential methylguanine-DNA methyltransferase (MGMT)
inhibitors. Their research resulted in two potent leads, the
ZINC000008220033 and ZINC000001529323 compounds, which
can be further optimized against the MGMT protein (Liu et al.,
2019).
There are existing computational studies targeted on the
development of the Axl kinase inhibitors. For instance, Fatima
et al. (2017) performed a docking simulation to understand the
compatibility of curcumin derivatives against a homology model
of the Axl kinase active site. Similarly, Mollard et al. (2011) used
an in silico approach to design the Axl kinase inhibitors. They
also performed a homology model of the binding site for such a
purpose. Moreover, these results were subsequently confirmed
by experimental data (Mollard et al., 2011). In both of the
above-mentioned cases, a homology model of the protein was
employed. In our study, we rely instead on the experimentally
solved 3D structure of the Axl kinase binding pocket (Gajiwala
et al., 2017), and for more accuracy, besides the extensive
molecular docking calculations, we additionally performed
the MMPBSA/GBSA simulations (see Wang et al., 2019 for
evaluation) to identify the best possible drug candidates. As the
highest affinity toward Axl kinase was defined for the crizotinib
and R428 molecules (see Table 1), they were further considered
as the parental “scaffolds” for in silico structural modifications.
Crizotinib was already applied as a first-line therapy for
the treatment of lung cancer (Awad and Shaw, 2014). This
medication is also active against the ALK and hepatocyte growth
factor receptor as proto-oncogene c-Met, especially in patients
with the ALK-rearranged non-small cell lung cancer after oral
administration (Awad and Shaw, 2014). However, most of the
crizotinib-based modifications represented only a slight binding
improvement to the Axl protein (Table S2; compounds C1–C10).
Crizotinib and the related compounds, in line with this, work
only for some time, and then there is a resistance observed in the
clinic (Awad and Shaw, 2014).
On the other hand, R428 had proven to be a selective Axl
kinase inhibitor (Holland et al., 2010), with the inhibition
constant in the nanomolar (nM) range (Myers et al., 2016),
as well as the blocker of other Axl-associated events such as
autophosphorylation, metastasis development in breast cancer
and proinflammatory cytokine production (Holland et al., 2010).
In addition, R428 was found to induce apoptosis in many types
of cancer cells (Chen et al., 2018). Our findings concerning
R428-analog-based modifications demonstrate more promising
results than that of crizotinib. In particular, the designed drug
candidates—compounds R3, R5, and R10 (see Table 5) —possess
an improved binding property toward Axl compared to the
known type I inhibitors (see Table 1). Besides this, they are
also involved in the interaction with the D690, N677, M623,
and H625 residues (see Table 6) that are conserved for all TAM
family receptors according to the sequence alignment as shown
by Gajiwala et al. (2017). To evaluate the compatibility of the
compound R5 to Axl kinase, in Figure 8, for comparison, we
demonstrate ATP, R428, R428_1, and R5 inside the binding
pocket of Axl kinase. As the figure shows, ATP does not fit the
pocket well due to its small size (see Figure 8A) and, for this
reason, does not result in strong binding. R428 fits much better
than ATP (see Figure 8B), and, therefore, the binding score is
much higher than that of ATP. Compound R428_1, in turn, fits
even better than the compound R428 (see Figure 8C), resulting
in the highest score among the R428 analogs considered.
Finally, our best-designed drug candidate—compound R5 (see
Figure 8D)—shows the best fit and the strongest binding affinity
toward kinase.
The MD simulations are in strong accordance with the
molecular docking results, indicating a consistency between the
results obtained by two different methodologies. In particular,
the best binding molecular docking results were obtained for
the R5 compound compared to the parental R428 drug and
the best R428 patented analog—compound R428_1. These
findings were in agreement with the MM-PBSA calculations,
which were more optimized for these systems analyzed than
with the MM-GBSA approach (Table 8). The latter method
determined the second best affinity value for R5 to the Axl kinase
pocket after Axl–R428_1 (Table 9). The discrepancies in the
MM-PBSA/GBSA performances were previously emphasized
in the literature, showing that MM/PBSA performed better in
calculating absolute, but not always binding free energies than
MM-GBSA (Hou et al., 2011). Furthermore, the calculated K i
for R5 has shown the lowest value (Table 7), indicating its high
inhibition potency.
Additionally, the molecular-docking-based selectivity test was
performed by screening a set of kinases (ALK5, ABL1, FYN,
JAK1, Met, Tyro3, and Mer) to evaluate the binding affinity of
the compound R5 to them. Interestingly, this compound has
shown the strongest binding properties toward Tyro3, which
is another receptor of the TAM family. We tried to explain
this phenomenon by performing a comparative analysis for the
binding pockets of the high-scoring (Axl, Tyro3, and ABL1)
and the relatively low-scoring (MET) kinases (see Table 11). It
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FIGURE 8 | The ATP binding cavity on the surface of the Axl kinase and the drug accommodation inside the pocket. The ATP is shown in cyan (A), the compound
R428 is shown in green (B), the compound R428_1 is shown in yellow (C), and our best designed compound R5 is shown in red (D). The pocket is represented as a
surface, the protein chain is represented as a cartoon, the hydrophobic patches of the pocket are shown in light green, the hydrophilic patches are shown in purple,
and the hydrogen bond acceptors are shown in red. The compounds in the pocket are represented as a licorice.
is clear from the molecular docking poses (see Figure 9) that
R5 exhibits a “stretched” conformation inside the binding sites
of Axl, Tyro3, and ABL1 and a “shrunk” form in the MET.
There are four residues (D690, E546, D627, and G626) of the
Axl pocket involved in the interaction with R5 (Figure S1A).
Compared to the Axl pocket, five residues in the Tyro3 (K597,
M596, R512, D663, and K540) and the ABL1 (D325, E329, L248,
T315, and E316) pockets are involved in the interaction with R5
(see Figures S1B,C). In contrast, only three residues of the MET
pocket (K1161, Y1230, andD1164) are involved in the interaction
with R5 (Figure S1D). Therefore, we think that the 3D shape of
the binding sites as well as the number of interacting residues
influence the change in the binding scores. Furthermore, the Axl
and Tyro3 kinases were already investigated as important drug
targets for various types of cancers (Duan et al., 2016; Dantas-
Barbosa et al., 2017), expanding the possibility of R5 application
against different malignant tumors.
TAM activation can, thus, be efficiently inhibited by the small-
molecule inhibitors for this interaction. For the TAM activation
blocking compounds RU-301 and RU-302, Kimani et al. (2017)
suggested and experimentally observed that these may act as pan-
TAM inhibitors as they suppress the H1299 lung cancer tumor
growth in the mouse xenograft NOND-SCIDγ model tested.
Individual studies are, of course, limited to only either modeling
or experiments in vitro or in cell culture. Similarly, inhibiting
only one cancer pathway may not be the strongest strategy,
particularly in view of clinical application. However, there is now
consensus that, due to their well-established and clear inhibitory
effect on several cancer pathways such as cell survival, invasion,
migration, chemo-resistance, and metastasis, such TAM
inhibitors hold great promise for cancer treatment (Davra et al.,
2016). Moreover, further studies have shown that the TAM family
expression often correlates with poor clinical outcomes, and
there are several classes of promising TAM inhibitors according
to the accumulated experimental data (Davra et al., 2016).
We reveal here a particular promising TAM inhibitor derived
from the experimentally validated compound R428; this is
compound R5. We have, hence, good reasons, including the solid
experimental validation of closely related compounds and using
only well-established and experimentally validated methods and
compound scoring schemes, to suggest R5 as a novel anti-cancer
compound. However, this is, of course, only the starting point for
further research. To be sure, this needs even more experimental
data and subsequent compound-specific tests and clinical
trials. As a bioinformatics group, we hope to stimulate more
experimental research toward this end. Moreover, the molecular
approach of the TAM-receptor inhibition implemented here is
also a valuable strategy not only in cancer but also in hemostasis
and thrombosis and platelet function (Law et al., 2018), such that
the compound R5 should be explored and tested further and also
analyzed for such indications.
General Considerations and Caveats
It is, of course, possible to get a very high false-positive rate in the
virtual screening, but this canmainly happen if you do not do any
scoring or accept all targets equally well.
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FIGURE 9 | The 3D representation of the compound designed, R5, inside the binding pocket of the Axl (A), Tyro3 (B), ABL1 (C), and MET (D) kinases. The pocket is
shown as a van der Waals surface representation. The hydrophobic parts inside the pocket are shown in green, the hydrophilic parts are shown in purple, and the
hydrogen bond acceptors are shown in red. The ligand is shown as a licorice representation and depicted in forest green.
In particular, as the reader can see in our manuscript, the
chosen strategy strongly reduces the amount of false-positives.
We always start from the best possible leads, and that is not only
according to the scoring but also, more importantly, according to
all available experimental data.
Nevertheless, we think that it is necessary to validate the
proposed compounds with actual experiments, and that is the
reason why we want to publish our results here, considering
other purely theory articles such as those of Fu et al. (2019),
Duan et al. (2019), and Zheng et al. (2019). We acknowledge
that we highly value the hard work and the final proof of a
direct experiment, and the whole point of our publication is to
exactly simulate this.We also have a non-trivial result, i.e., several
strong pharmacological leads, including experimental validation
and their actual use in clinical settings, are incorporated and now
further optimized by us, yielding a top compound, among the
best candidates for an important and well-known cancer target,
that looks very promising by three different scoring schemes.
CONCLUSION
In summary, systematic computational studies were performed
to establish the best drug candidates for targeting Axl kinase to
treat cancer. The first compound selection has shown that the
most potent drugs for such a purpose are crizotinib, macrocyclic
compound 1, and R428. Further searches were performed based
on the analogs of pharmaceutically available drugs, namely,
crizotinib and R428. The docking results for crizotinib analogs
did not demonstrate scores higher than the original drug itself.
Therefore, we focused on crizotinib by modifying it further. The
R428 analog docking resulted in four high-scoring compounds,
which were further utilized for structural modifications. The
structural modifications of crizotinib did not show any significant
Axl binding improvements, while modifications of the R428
analogs resulted in a new potential drug candidate—compound
R5. Apart from the docking tests, the potency of this newly
designed compound as an Axl kinase inhibitor has been
confirmed by a molecular dynamics simulation in terms of
protein–ligand complex stability. Furthermore, an in silico
selectivity test against other kinases has also shown a high affinity
of R5 toward ABL1 and Tyro3. Our in silico results suggest the
application of the newly designed compound R5 particularly as
an anti-cancer agent. Direct proof by experiment is now the
next important step. Further synthesis and in vitro tests of this
compound against various cancer cell lines, where Axl, ABL1,
and Tyro3 play a significant role in proliferation, division and
metastases are further steps to be taken, and further indications
for TAM inhibition may follow.
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